HK1166805A1 - 抗- 抗體和免疫綴合物以及應用方法 - Google Patents

抗- 抗體和免疫綴合物以及應用方法

Info

Publication number
HK1166805A1
HK1166805A1 HK12107358.7A HK12107358A HK1166805A1 HK 1166805 A1 HK1166805 A1 HK 1166805A1 HK 12107358 A HK12107358 A HK 12107358A HK 1166805 A1 HK1166805 A1 HK 1166805A1
Authority
HK
Hong Kong
Prior art keywords
fcrh5
immunoconjugates
methods
antibodies
fcrh5 antibodies
Prior art date
Application number
HK12107358.7A
Other languages
English (en)
Inventor
克里斯蒂．埃爾金斯
安德魯．保爾森
艾倫．埃本斯
卡梅利婭．亞當斯
鄭冰
杰加斯．
．尤努圖拉
喬安妮．洪格
吳岩
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1166805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1166805A1 publication Critical patent/HK1166805A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK12107358.7A 2009-04-01 2012-07-26 抗- 抗體和免疫綴合物以及應用方法 HK1166805A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21175409P 2009-04-01 2009-04-01
US16621409P 2009-04-02 2009-04-02
PCT/US2010/029521 WO2010114940A1 (en) 2009-04-01 2010-03-31 Anti-fcrh5 antibodies and immunoconjugates and methods of use

Publications (1)

Publication Number Publication Date
HK1166805A1 true HK1166805A1 (zh) 2012-11-09

Family

ID=42236394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107358.7A HK1166805A1 (zh) 2009-04-01 2012-07-26 抗- 抗體和免疫綴合物以及應用方法

Country Status (19)

Country Link
US (2) US8362213B2 (zh)
EP (1) EP2414395A1 (zh)
JP (2) JP6099976B2 (zh)
KR (1) KR20120003478A (zh)
CN (1) CN102369218B (zh)
AR (1) AR076030A1 (zh)
AU (1) AU2010232682A1 (zh)
BR (1) BRPI1012560A2 (zh)
CA (1) CA2756988A1 (zh)
CL (1) CL2011002418A1 (zh)
HK (1) HK1166805A1 (zh)
IL (1) IL215404A0 (zh)
MX (1) MX2011010265A (zh)
PE (1) PE20120877A1 (zh)
RU (2) RU2583270C2 (zh)
SG (1) SG174930A1 (zh)
TW (1) TW201039846A (zh)
WO (1) WO2010114940A1 (zh)
ZA (1) ZA201107128B (zh)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2714684B1 (en) * 2011-05-27 2018-09-05 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP5926374B2 (ja) 2011-06-10 2016-05-25 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
AU2014214751B2 (en) * 2013-02-08 2017-06-01 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
TWI666026B (zh) 2013-03-29 2019-07-21 日商大日本住友製藥股份有限公司 Ｗｔ１抗原胜肽結合疫苗
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
BR112015032200A2 (pt) 2013-06-24 2017-11-21 Hanwha Chemical Corp conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo
AR096687A1 (es) * 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
ES2726850T3 (es) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
RS60443B1 (sr) 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
TW201625690A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｃｌｌ－１抗體及免疫結合物
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
NZ732570A (en) 2014-12-05 2022-12-23 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
WO2016205176A1 (en) * 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
UA124615C2 (uk) * 2015-06-16 2021-10-20 Дженентек, Інк. АНТИТІЛО ПРОТИ ПОДІБНОГО ДО Fc-РЕЦЕПТОРА БІЛКА 5 (FcRH5)
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
SG11201804656PA (en) * 2015-12-04 2018-06-28 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
WO2017188346A1 (ja) * 2016-04-27 2017-11-02 国立大学法人 東京大学 マイクロファイバーを用いた血中循環細胞の捕捉及び回収用材料及び当該材料を用いる方法
SG11201811292RA (en) * 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cells
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2019015057A (es) * 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
CA3072153A1 (en) * 2017-08-10 2019-02-14 Sumitomo Dainippon Pharma Co., Ltd. Antibody-drug conjugates including hemiasterlin derivative
EP3666788A4 (en) * 2017-08-10 2021-05-05 Sumitomo Dainippon Pharma Co., Ltd. HEMIASTERLIN DERIVATIVES AND ANTIBODY-ACTIVE INGREDIENT CONJUGATES CONTAINING THESE
US10766613B2 (en) * 2017-11-28 2020-09-08 Textron Innovations Inc. System and method for rotorcraft-weight-on-wheels flight state transition control
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020023106A1 (en) * 2018-07-25 2020-01-30 Northeastern University Selectivity screening for antimicrobial compounds
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
BR112021011874A2 (pt) 2018-12-20 2021-09-08 Novartis Ag Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2020166592A1 (ja) * 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
JP2022547574A (ja) 2019-09-11 2022-11-14 インケア バイオテック， エルエルシー 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
CR20230210A (es) 2019-12-13 2023-06-14 Genentech Inc ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies that bind to cd38
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022026202A2 (pt) 2020-06-23 2023-01-17 Novartis Ag Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
AR127568A1 (es) 2021-11-03 2024-02-07 Affimed Gmbh Ligandos biespecíficos de cd16a
WO2023201299A1 (en) * 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN116199772B (zh) * 2022-11-16 2023-10-17 怡道生物科技(苏州)有限公司 Hpv31型衣壳蛋白l1单克隆抗体、制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE69434136T2 (de) 1993-10-01 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. Dolastatin-derivate
US20020132252A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
ES2568625T3 (es) * 1999-11-29 2016-05-03 The Trustees Of Columbia University In The City Of New York Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040005561A1 (en) 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
JP2005511627A (ja) 2001-11-20 2005-04-28 シアトル ジェネティクス，インコーポレーテッド 抗ｃｄ３０抗体を使用する免疫学的疾患の治療
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
CN101065151B (zh) * 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
CA2594318A1 (en) * 2005-01-12 2006-07-20 Medarex, Inc. Irta-2 antibodies and their uses
BRPI0622254A2 (pt) * 2005-06-20 2011-08-09 Genentech Inc anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica
WO2008109533A2 (en) 2007-03-02 2008-09-12 Medarex, Inc. Human antibodies that bind multiple irta family proteins, and uses thereof
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso

Also Published As

Publication number Publication date
US20110171125A1 (en) 2011-07-14
WO2010114940A1 (en) 2010-10-07
CN102369218A (zh) 2012-03-07
RU2583270C2 (ru) 2016-05-10
CN102369218B (zh) 2014-07-16
JP2016028052A (ja) 2016-02-25
MX2011010265A (es) 2011-10-11
EP2414395A1 (en) 2012-02-08
AU2010232682A1 (en) 2011-11-10
US9017951B2 (en) 2015-04-28
RU2016110891A (ru) 2018-11-27
SG174930A1 (en) 2011-11-28
BRPI1012560A2 (pt) 2016-07-26
AR076030A1 (es) 2011-05-11
TW201039846A (en) 2010-11-16
KR20120003478A (ko) 2012-01-10
JP6099976B2 (ja) 2017-03-29
PE20120877A1 (es) 2012-08-06
IL215404A0 (en) 2011-12-29
US8362213B2 (en) 2013-01-29
CA2756988A1 (en) 2010-10-07
ZA201107128B (en) 2012-12-27
CL2011002418A1 (es) 2012-03-16
US20130089497A1 (en) 2013-04-11
JP2012522513A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
HK1166805A1 (zh) 抗- 抗體和免疫綴合物以及應用方法
IL215402A0 (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
IL250624B (en) Anti-fgfr3 antibodies and methods of using them
ZA201005351B (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
IL215795A0 (en) Anti-il-17f antibodies and methods of use thereof
HUE042940T2 (hu) Anti-FXI antitestek és alkalmazási eljárások
IL211623A0 (en) Anti-notch2 antibodies and methods of use
IL222514A0 (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
IL219136A0 (en) Anti-hepsin antibodies and methods using same
TH0901000138A (th) แอนติ-cd79b แอนติบอดีและอิมมูโนคอนจูเกตและวิธีการใช้งาน

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190403